Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in...

Details Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in... Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in...

2005-12-05

2010-11-09

Wilson, James O (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C514S265100

Reexamination Certificate

active

07829707

ABSTRACT:
There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.

REFERENCES:
patent: 3135753 (1964-06-01), Hitchings et al.
patent: 4820709 (1989-04-01), Hofer
patent: 5173491 (1992-12-01), Kamoun et al.
patent: 5489598 (1996-02-01), Connor et al.
patent: 5716967 (1998-02-01), Kleinman
patent: 5756511 (1998-05-01), West et al.
patent: 5976823 (1999-11-01), Wu
patent: 6025361 (2000-02-01), Cavalla et al.
patent: 6046019 (2000-04-01), Goumeniouk et al.
patent: 6066641 (2000-05-01), Cavalla et al.
patent: 6294541 (2001-09-01), Cavalla et al.
patent: 6319928 (2001-11-01), Chasin et al.
patent: 7108997 (2006-09-01), Kettle
patent: 2004/0022871 (2004-02-01), Mainnemare
patent: 2004/0029871 (2004-02-01), Thong et al.
patent: 2005/0070558 (2005-03-01), Vidal Juan et al.
patent: 2005/0234036 (2005-10-01), Hanson et al.
patent: 2007/0032468 (2007-02-01), Kettle et al.
patent: 2007/0093483 (2007-04-01), Svensson et al.
patent: 1013676 (1991-08-01), None
patent: 0010531 (1982-06-01), None
patent: 0359505 (1990-03-01), None
patent: 0430300 (1991-06-01), None
patent: 0452926 (1996-03-01), None
patent: 01016407 (2006-05-01), None
patent: 02160235 (1990-06-01), None
patent: 8906125 (1989-07-01), None
patent: 9500516 (1995-01-01), None
patent: 9618400 (1996-06-01), None
patent: 9914204 (1999-03-01), None
patent: 9917773 (1999-04-01), None
patent: 9936073 (1999-07-01), None
patent: 9940091 (1999-08-01), None
patent: 0051598 (2000-09-01), None
patent: 0059449 (2000-10-01), None
patent: 0185146 (2001-11-01), None
patent: 0206272 (2002-01-01), None
patent: 0208237 (2002-01-01), None
patent: 02066447 (2002-08-01), None
patent: 02090575 (2002-11-01), None
patent: 03000694 (2003-01-01), None
patent: 03082873 (2003-10-01), None
patent: 03089430 (2003-10-01), None
patent: 2004096781 (2004-11-01), None
patent: 2005037835 (2005-04-01), None
patent: 2005042534 (2005-05-01), None
patent: 2005077950 (2005-08-01), None
patent: 2006045564 (2006-05-01), None
patent: 2006046910 (2006-05-01), None
patent: 2007142576 (2007-12-01), None
Lim et. al. (Journal of Organic Chemistry, 1979, 44(22) pp. 3826-3829).
Grehn (Chemica Scripta, 1980, 16(3) pp. 77-84).
Parry et al., “Myeloperoxidase Deficiency, Prevalence and Clinical Signficance,” Ann Int Med., 1981, vol. 95, pp. 293-301.
Pesci et al., “Inflammatory Cells and Mediators in Bronchial Lavage of Patients with Chronic Obstructive Pulmonary Disease,” European Respiratory Journal, 1998, vol. 12, pp. 380-386.
Peskin et al., “Kinetics of the Reactions of Hypochlorous Acid and Amino Acid Chloramines with Thiols, Methionine, and Ascorbate,” Free Radical Biology and Medicine, 2001, vol. 30(5), pp. 572-579.
Peskin et al., “Chlorine Transfer Between Glycine, Taurine, and Histamine: Reaction Rates and Impact of Cellular Reactivity,” Free Radical Biology and Medicine, 2004, vol. 37(10), pp. 1622-1630.
Rao et al., “Synthesis of 5,7-Disubstituted-4-Beta-D-ribofuranosylpyrazolo[4,3-d]-pyrimidines and 2,4-Disubstituted-1-Beta-D-ribofuranosylpyrrolo[3,2-d]-pyrimidines as Congeners of Uridine and Cytidine,” J. Heterocyclic Chemistry, 1992, vol. 29, pp. 343-354.
Rosen et al., “Oxidation ofEscherichia coliIron Centers by the Myeloperoxidase-mediated Microbicidal System,” Journal of Biological Chemistry, 1982, vol. 257(22), pp. 13731-13735.
Shao et al., “Tyrosine 192 in Apolipoprotein A-I is the Major Site of Nitration and Chlorination by Myeloperoxidase, but only Chlorination Markedly Impairs ABCA1-Dependent Cholesterol Transport,” Journal of Biological Chemistry, 2005, vol. 280(7), pp. 5983-5993.
Sugiyama, S. et al., “Macrophage Myeloperoxidase Regulation by Granulocyte Macrophage Colony-Stimulating Factor in Human Atherosclerosis and Implications in Acute Coronary Syndromes,” Am J Pathol, 2001, pp. 879-891, vol. 158, No. 3.
Suzuki et al., “Assay method for myeloperoxidase in human polymorphonuclear leukocytes,” Analytical Biochemistry, 1983, vol. 132, pp. 345-352.
Suzuki et al., “Synthesis and Cyclic AMP Phosphodiesterase 4 Isoenzyme Inhibitory Activity of Heterocycle Condensed Purines,” Chem. Pharm. Bull., 2002, vol. 50(9), pp. 1163-1168.
Van Galen et al., “A Binding Site Model and Structure-Activity Relationships for the Rat A3 Adenosine Receptor,” Molecular Pharmacology, 1994, vol. 45, pp. 1101-1111.
Van Zyl et al., “Interaction of methylxanthines with myeloperoxidase. An anti-inflammatory mechanism,” Intnl J. of Biochem, 1992, vol. 24(6), pp. 929-935.
Wacker et al., “CCR3 Antagonists: A Potential New Therapy for the Treatment of Asthma. Discovery and Structure—Activity Relationships,” Bioorganic & Medicinal Chemistry Letters, 2002, vol. 12, pp. 1785-1789.
Wolfe et al., “Scope and Limitations of the Pd/BINAP-Catalyzed Amination or Aryl Bromides,” Journal of Organic Chemistry, 2000, vol. 65, pp. 1144-1157.
Woo et al., “Inhibitors of Human Purine Nucleoside Phosphorylase. Synthesis and Biological Activities of 8-Amino-3-benzylhypoxanthine and Related Analogues,” J. Med. Chem., 1992; vol. 35, pp. 1451-1457.
Wooldridge et al., “The Synthesis of Some 6-Thioxanthines,” J. Chem. Soc., 1962, pp. 1863-1868.
Yang et al., “Granulocyte Function Disorders: Aspects of Development, Genetics and Management,” Pediatric Infectious Disease Journal, 2001, vol. 20, pp. 889-900.
Yong et al., “Metalloproteinases in Biology and Pathology of the Nervous System,” Nature Reviews Neuroscience, 2001, vol. 2(7), pp. 502-511.
Zhang, R. et al.,“Association Between Myeloperoxidase Levels and Risk of Coronary Artery Disease,” Jama, 2001, pp. 2136-2142, vol. 286, No. 17.
Zheng et al., “Localization of Nitration and Chlorination Sites on Apolipoprotein A-I Catalyzed by Myeloperoxidase in Human Atheroma and Associated Oxidative Impairment in ABCA1-Dependent Cholesterol Efflux from Macrophages,” Journal of Biological Chemistry, 2005, vol. 280(1), pp. 38-47.
Zheng et al., “Apolipoprotein A-I is a Selective Target for Myeloperoxidase-Catalyzed Oxidation and Functional Impairment in Subjects with Cardiovascular Disease,” Journal of Clinical Investigation, 2004, vol. 114(4), pp. 529-541.
STN Intnl, CAPLUS Accession No. 1968:434597, Doc No. 69:34597, Dietz et al., “The hypnotic properties of 8-ethylthio-6-thiotheophylline sodium” & Toxicology and Applied Pharm., 1968, vol. 12, pp. 202-206.
STN Intnl, CAPLUS Accession No. 1966:420839, Doc No. 65:20839, Dietz et al., “The synthesis and pharmacologic evaluation of a series of 8-alkylthio-thiated theophyylines” & J. of Med Chem., 1966, vol. 9(4), pp. 500-506.
STN Intnl, CAPLUS Accession No. 1966:35888, Doc No. 64:35888, Dietz et al., “Synthesis of some 8-alkylthio-2-thiotheophyllines and 8-alkylthio-6-thiotheophyllines” & J. of Med Chem., 1966, vol. 9(1), p. 160.
STN Intnl CAPLUS Accession No. 1974:82889, No. 80:82889, Reichman, Uri et al., “Tautomerism, ionization and methylation of 2(methylthio)- and 2,8-bis(methyl-thio)hypoxanthines” & J. of the Chem. Soc., Perkin Transactions 1:Organic & BioOrganic Chem, 1972-1999, (22), 2647-55, 1973.
STN Intnl, File CAPLUS Accession No. 1984:630460, Doc No. 101:230460, Talukdar, P.B. et al., “Studies on ring-fused mesoionic thiazolo(3,2-a) imidazolo(4,5-d)pyrimidine derivatives,” & Indian J. of Chem, Section B: Organic Chem. Including Medicinal Chem, 23B(4), pp. 316-320, 1984.
STN Intnl, file Registry, 2H-Purin-2-one, 1,3,6,7-tetrahydro-8-(methyl

Affiliated with

Also associated with

Rating

Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4216983